Human papillomavirus vaccines: new tools for accelerating cervical cancer prevention in developing countries

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Zur Hausen H, Meinhof W, Scheiber W, Bornkamm GW: Int. J. Cancer13,650–656 (1974).
  Medline CASGoogle Scholar
• 2  Ferlay J, Bray F, Pisani P, Parkin DM: GLOBOCAN 2002 Cancer Incidence, Mortality and Prevalence Worldwide, Version 2.0. IARC Press, IARC CancerBase No. 5, Lyon, France (2004).
  Google Scholar
• 3  Parkin MD, Bray F: The burden of HPV related cancers. Vaccine24S3,S3/11–S3/25 (2006).
  Google Scholar
• 4  Arrossi S, Ramos S, Paolino M, Sankaranarayanan R: Social inequality in Pap smear coverage: identifying under- users of cervical cancer screening in Argentina. Reprod. Health Matters16(32),50–58 (2008).
  MedlineGoogle Scholar
• 5  Murillo R, Almonte M, Pereira A et al.: Cervical cancer screening programs in Latin America and the Caribbean. Vaccine26S,L37–L48 (2008).
  Google Scholar
• 6  International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 90, Human Papillomaviruses. IARC Press. Lyon, France (2005).
  Google Scholar
• 7  Andrus JK, Lewis M, Goldie SJ et al.: Human papillomavirus vaccine policy and delivery in Latin America and the Caribbean. Vaccine26 (Suppl. 11),L80–L87 (2008).
  MedlineGoogle Scholar
• 8  Schiffman M, Castle PE, Jeronimo J, Rodriquez AC, Wacholder S: Human papillomavirus and cervical cancer. Lancet370,890–907 (2007).
  Medline CASGoogle Scholar
• 9  World Health Organization: Comprehensive cervical cancer control: a guide to essential practice. World Health Organization, Geneva, Switzerland (2006).
  Google Scholar
• 10  Muñoz N, Castellsagué X, Berrington A, Gissmann L: HPV in the etiology of human cancer. Vaccine24S3,S3/1–S3/10 (2006).
  Google Scholar
• 11  Almonte M, Albero G, Molano M, Carcamo C, Garcia P, Perez G: Risk factors for human papillomavirus exposure and co-factors for cervical cancer in Latin America and the Caribbean. Vaccine26S,L16–L36 (2008).
  Google Scholar
• 12  Castellsagué X, Sanjosé S, Aguado T et al.: HPV and cervical cancer in the world 2007 report. Vaccine25S,C1–C26 (2007).▪▪ Summarizes key data by country on human papillomavirus (HPV) prevalence, HPV type and cervical cancer.
  Google Scholar
• 13  Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer88,63–73 (2003).
  Medline CASGoogle Scholar
• 14  Schmiedeskamp MR, Kockler DR: Human papillomavirus vaccines. Ann. Pharmacother.40,1344–1352 (2006).
  Medline CASGoogle Scholar
• 15  Nishida KJ, Pearson JM, Twiggs LB: Cross-protection from human papillomavirus 16/18 against types 45 and 31: fact or fancy? Therapy5(3),265–268 (2008).
  CASGoogle Scholar
• 16  Govan VA: A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil^®). Ther. Clin. Risk Manag.4(1),65–70 (2008).
  Medline CASGoogle Scholar
• 17  Chaplin S, Nicholas N: Cervarix^®, a bivalent HPV vaccine to prevent cervical cancer. Prescriber.19(18),46–49 (2008).
  Google Scholar
• 18  Schiller JT, Castellsagué X, Villa LL, Hildesheim A: An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine26(10),K53–K61 (2008).
  Medline CASGoogle Scholar
• 19  Dawar M, Deeks S, Dobson S: Public health – perspectives on HPV, human papillomavirus vaccines launch a new era in cervical cancer prevention. CMAJ177(5),456–461 (2007).
  MedlineGoogle Scholar
• 20  Kulasingam SL; Myers ER: Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA290(6),781–789 (2003).
  MedlineGoogle Scholar
• 21  World Health Organization. Human papillomavirus vaccines: WHO position paper. Weekly Epidemiological Record15(84),118–131 (2009)
  Google Scholar
• 22  Hymel PA: Decreasing risk: impact of HPV vaccination on outcomes. Am. J. Manag. Care12(17),S473–S483 (2006).
  MedlineGoogle Scholar
• 23  Stanley M: Prophylactic HPV vaccines. J. Clin. Pathol.60,961–965 (2007).
  MedlineGoogle Scholar
• 24  Cutts FT, Franceschi S, Goldie S et al.: Human papillomavirus and HPV vaccines: a review. Bull. WHO85(9),719–726 (2007).
  Medline CASGoogle Scholar
• 25  Kohls A: Current and future HPV vaccines: promises and challenges. Path1–72 (2006).
  Google Scholar
• 26  Herrero R: Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J. Infect. Dis.199,919–922 (2009).
  MedlineGoogle Scholar
• 27  Fraser C, Tomassini JE, Xi L et al.: Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic Vaccine. Vaccine25(21),4324–4333 (2007).
  Medline CASGoogle Scholar
• 28  Wheeler CM: Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing. Nat. Clin. Pract. Oncol.4(4),224–35 (2007).
  MedlineGoogle Scholar
• 29  Koulova A, Tsui J, Irwin K, Van Damme P, Biellik R, Aguado MT: Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006–January 2008. Vaccine26,6529–6541 (2008).
  MedlineGoogle Scholar
• 30  Tucker ME: Gardasil prevents HPV infection in teen boys. Pediatric News43(3),6 (2009).
  Google Scholar
• 31  Petäjä T, Keränen H, Karppa T et al.: Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10–18 years. J. Adolesc. Health44,33–40 (2009).
  MedlineGoogle Scholar
• 32  Goldie SJ, O’Shea M, Diaz M, Kim SY: Benefits, cost requirements and cost–effectiveness of the HPV16, 18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod. Health Matters16(32),86–96 (2008).
  MedlineGoogle Scholar
• 33  Hildesheim A, Markowitz L, Hernandez AM, Franceschi S: Chapter 27: research needs following initial licensure of virus-like particle HPV vaccines. Vaccine24(3),S227–S232 (2006).
  Google Scholar
• 34  Shiller JT, Nardelli-Haeflinger DN: Second generation HPV vaccines to prevent cervical cancer. Vaccine24(S3),147–153 (2006).
  Google Scholar
• 35  Andrus JK, Dietz V, Fitzsimmons JW, Castillo-Solórzano C: Accelerating policy, deployment and access to new and underutilized vaccines in developing countries. Harvard Health Policy Review7(2),91–101 (2006).
  Google Scholar
• 36  Gonik B: Strategies for fostering HPV vaccine acceptance. Infect. Dis. Obstet. Gynecol. (Suppl. 36797) 1–4 (2006).
  Google Scholar
• 37  Brabin L, Roberts SA, Farzaneh F, Kitchener HC: Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes. Vaccine24,3087–3094 (2006).
  MedlineGoogle Scholar
• 38  Stanley M, Villa LL: Monitoring HPV vaccination. Vaccine26S,A24–A27 (2008).
  Google Scholar
• 39  Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S: A critical assessment of screening methods for cervical neoplasia. Int. J. Gyn. Obst.89,S4–S12 (2005).▪ Summarizes data on cervical cancer screening test effectiveness.
  MedlineGoogle Scholar
• 40  Hakama M, Chamberlain J, Day NE, Miller AB, Prorok PC: Evaluation of screening programmes for gynaecological cancer. Br. J. Cancer52,669–673 (1985).
  Medline CASGoogle Scholar
• 41  Public Health Agency of Canada. Cervical Cancer Screening in Canada: Surveillance Report. Ottawa, Canada (1998).
  Google Scholar
• 42  Sherlaw-Johnson C, Gallivan S, Jenkins D: Evaluating cervical cancer screening programmes for developing countries. Int. J. Cancer72,210–216 (1997).
  Medline CASGoogle Scholar
• 43  International Agency for Research on Cancer: IARC Handbooks of Cancer Prevention: Cervical Cancer Screening. IARC Press. Lyon, France (2005).
  Google Scholar
• 44  World Health Organization: National Cancer Control Programmes: Policies and Managerial Guidelines. Geneva, Switzerland (2002).
  Google Scholar
• 45  Sankaranarayanan R, Nene BM, Shastri SS et al.: HPV screening for cervical cancer in rural India. N. Engl. J. Med.360(14),1–10 (2009).▪▪ Highlights the significant mortality reduction in cervical cancer with HPV screening in a low-resource setting.
  MedlineGoogle Scholar
• 46  Qiao Y, Sellors J, Eder PS et al.: A new HPV DNA test for cervical cancer screening in developing regions: a cross sectional study of clinical accuracy in rural China. Lancet Oncol.9(10),929–936 (2008).
  MedlineGoogle Scholar
• 47  Gamboa O, Chicaiza L, Garcia-Molina M, Diaz J, Gonzalez M, Murillo R: Cost effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia. Salud Publica Mex.50(4),276–85 (2008).
  MedlineGoogle Scholar
• 48  University of Zimbabwe, JHPIEGO Cervical Cancer Project: Visual inspection with acetic acid for cervical cancer screening: test qualities in a primary-care setting. Lancet353,869–873 (1999).
  MedlineGoogle Scholar
• 49  Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD et al.: Cost–effectiveness of cervical-cancer screening in five developing countries. N. Engl. J. Med.353(20),2158–2168 (2005).
  Medline CASGoogle Scholar
• 50  Gaffikin L, Blumenthal PD, Emerson M, Limpaphayom K: Safety, acceptability, and feasibility of a single-visit approach to cervical-cancer prevention in rural Thailand: a demonstration project. Lancet361(9360),814–820 (2003).
  Medline CASGoogle Scholar
• 51  Sankaranarayanan R, Esmy PO, Rajkumar R et al.: Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet370(9585),398–406 (2007).▪▪ Highlights impact of screening with visual inspection screening in a low-resource setting.
  MedlineGoogle Scholar
• 52  Garnett GP, Kim JJ, French K, Goldie S: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine26S/S3,178–186 (2006).
  Google Scholar
• 53  Goldie SJ, Diaz M, Constelna D, Alvis N, Andrus JK, Kim SY: Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine26(Suppl. 11),L59–L72 (2008).▪▪ Presents cost–effectiveness data on HPV vaccines and screening strategies.
  MedlineGoogle Scholar
• 54  Franco EL, Cuzick J, Hildesheim A, Sanjose S: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine26S/S3,171–177 (2006).
  Google Scholar
• 55  Zimet GD, Liddon N, Rosenthal S, Lazcano-Ponce E, Allen B: Psychosocial aspects of vaccine acceptability. Vaccine24S3,201–209 (2006).
  Google Scholar
• 56  World Health Organization. Human Papillomavirus and HPV vaccines: Technical Information for Policy Makers and Health Professionals. WHO, Geneva, Switzerland. (2007).
  Google Scholar
• 57  Sherris J, Friedman A, Wittet S, Davies P, Steben M, Saraiya M: Education, training and communication for HPV vaccines. Vaccine24S3,210–218 (2006).
  Google Scholar
• 58  Andrus JK, Toscano C, Lewis M et al.: A model for enhancing evidenced-based capacity to make informed policy decisions on the introduction of new vaccines in the Americas: PAHO’s ProVac Initiative. Public Health Reports122(6),811–816 (2007).
  MedlineGoogle Scholar
• 59  Andrus JK, Sherris J, Fitzsimmons J, Kane M, Aguado T: Introduction of human papillomavirus vaccines into developing countries – international strategies for funding and procurement. Vaccine26(Suppl. 10),K87–K92 (2008).
  MedlineGoogle Scholar
• 101  Miller N: Medical officer’s review of biologics license application supplement for human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant (Gardasil^®). US FDA 2008 www.fda.gov/downloads/Biologicsbloodvaccines/vaccines/approvedproducts/UCM111274.pdf (Accessed 26 June 2009).
  Google Scholar
• 102  Naveke A: Sanofi pasteur MSD release: Gardasil. Drug information online. www.drugs.com/clinicaltrials/spmsd-release-gardasil-3534.html (Acessed 16 March 2009).
  Google Scholar